BioCentury | Apr 22, 2020
Finance

April 21 Financial Quick Takes: ORIC’s IPO plans; plus venture rounds for Magpie, Cloudbreak, ReAlta, New Horizon, Zikani

...Cloudbreak licensed manufacturing and commercialization rights for CBT-001, a version of pulmonary fibrosis drug Ofev nintedanib...
BioCentury | Mar 10, 2020
Product Development

March 9 Quick Takes: A first for Boehringer’s Ofev; plus Cel-Sci’s COVID-19 therapy, Sinopharm, AZ, Urovant, Hengrui, Trevena, and Tetra-Shionogi

...Boehringer’s Ofev approved as first therapy for lung scarring disease FDA approved Ofev nintedanib from Boehringer...
BioCentury | Feb 29, 2020
Regulation

Lilly’s Emgality fails to win CHMP support for cluster headaches

...bacterial infections in adults with limited treatment options. CHMP also backed label extensions for Ofev nintedanib...
...lymphoma kinase CGRP - Calcitonin gene-related peptide Sandi Wong, Assistant Editor Emgality, galcanezumab-gnlm (LY2951742) Vargatef, nintedanib (BIBF 1120, ofev, BIBF1120) Alunbrig...
BioCentury | Jan 25, 2020
Emerging Company Profile

Aluda: targeting the fundamentals

...more than Ofev nintedanib from Boehringer Ingelheim GmbH and Pirfenex pirfenidone from Roche (SIX:ROG; OTCQX:RHHBY). Ofev...
BioCentury | Jan 10, 2020
Company News

Boehringer continues fibrosis drive via acquisition of Enleofen assets

...its success in fibrosis, which started in 2014 when FDA approved its IPF drug Ofev nintedanib...
BioCentury | Dec 19, 2019
Finance

Boehringer deal, clinical milestones support Bridge IPO

...of BBT-877 to treat idiopathic pulmonary fibrosis (IPF), an indication where Boehringer already markets Vargatef nintedanib...
BioCentury | Sep 6, 2019
Company News

Sept. 6 Company Quick Takes: Soliris patents denied; plus Novartis, Roche, Lilly and Boehringer

...Promote Clinical Trial Innovation" ). Boehringer's Ofev approved for rare lung condition FDA approved Ofev nintedanib...
...treat systemic sclerosis interstitial lung disease, the first therapy approved for the rare lung condition. Ofev...
...RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Vargatef, nintedanib (BIBF 1120, ofev, BIBF1120) Alexion...
BioCentury | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

...which kicked off in 2014 when FDA approved its idiopathic pulmonary fibrosis (IPF) drug Ofev nintedanib...
BioCentury | Jul 26, 2019
Company News

July 25 Company Quick Takes: RegenxBio, Neurimmune in neurodegenerative gene therapy deal; plus Lilly, Epizyme, ElevateBio and more

...Ofev in lung disease FDA's Arthritis Advisory Committee voted 10-7 to recommend the approval of Ofev...
...in lung disease FDA's Arthritis Advisory Committee voted 10-7 to recommend the approval of Ofev nintedanib...
...factor receptor; VEGF - Vascular endothelial growth factor BioCentury Staff NB-01, DA-9801 NKTR-181 tazemetostat (E7438, EPZ-6438) Vargatef, nintedanib (BIBF 1120, ofev, BIBF1120) Boehringer...
BioCentury | Jul 18, 2019
Company News

Boehringer deal enables Bridge to expand pipeline, take in-house programs further

...further builds a fibrosis pipeline that would extend its franchise beyond marketed IPF drug Ofev nintedanib...
Items per page:
1 - 10 of 92